tetano
Editor, Senior Moderator
J Virol. 2012 Nov 21. [Epub ahead of print]
A Sendai virus derived RNA agonist of RIG-I as a viral vaccine adjuvant.
Mart?nez-Gil L, Goff PH, Hai R, Garc?a-Sastre A, Shaw ML, Palese P.
Source
Department of Microbiology.
Abstract
The innate immune system is responsible for recognizing invading pathogens and initiating a protective response. In particular, the Retinoic acid-Inducible Gene 1 protein (RIG-I) participates in the recognition of single and double stranded RNA viruses. RIG-I activation leads to the production of an appropriate cytokine and chemokine cocktail that stimulates an antiviral state and drives the adaptive immune system towards an efficient and specific response against the ongoing infection. One of the best characterized natural RIG-I agonists is the defective interfering (DI) RNA produced by Sendai virus Cantell strain. This 546 nucleotide RNA is a well known activator of the innate immune system and an extremely potent inducer of type I interferon. We designed an in vitro transcribed RNA that retains the type I interferon stimulatory properties and the RIG-I affinity of the Sendai virus produced DI RNA both in vitro and in vivo. This in vitro synthesized RNA is capable of enhancing the production of anti-influenza HA-specific IgG after intra-muscular or intra-nasal co-administration with inactivated H1N1 2009 pandemic vaccine. Furthermore, our adjuvant is equally effective at increasing the efficiency of an influenza A/Puerto Rico/8/34 inactivated vaccine as poly I:C- or a squalene-based adjuvant. Our in vitro transcribed DI RNA represents an excellent tool for the study of RIG-I agonists as vaccine adjuvants and a starting point in the development of such vaccine.
PMID:
23175362
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23175362
A Sendai virus derived RNA agonist of RIG-I as a viral vaccine adjuvant.
Mart?nez-Gil L, Goff PH, Hai R, Garc?a-Sastre A, Shaw ML, Palese P.
Source
Department of Microbiology.
Abstract
The innate immune system is responsible for recognizing invading pathogens and initiating a protective response. In particular, the Retinoic acid-Inducible Gene 1 protein (RIG-I) participates in the recognition of single and double stranded RNA viruses. RIG-I activation leads to the production of an appropriate cytokine and chemokine cocktail that stimulates an antiviral state and drives the adaptive immune system towards an efficient and specific response against the ongoing infection. One of the best characterized natural RIG-I agonists is the defective interfering (DI) RNA produced by Sendai virus Cantell strain. This 546 nucleotide RNA is a well known activator of the innate immune system and an extremely potent inducer of type I interferon. We designed an in vitro transcribed RNA that retains the type I interferon stimulatory properties and the RIG-I affinity of the Sendai virus produced DI RNA both in vitro and in vivo. This in vitro synthesized RNA is capable of enhancing the production of anti-influenza HA-specific IgG after intra-muscular or intra-nasal co-administration with inactivated H1N1 2009 pandemic vaccine. Furthermore, our adjuvant is equally effective at increasing the efficiency of an influenza A/Puerto Rico/8/34 inactivated vaccine as poly I:C- or a squalene-based adjuvant. Our in vitro transcribed DI RNA represents an excellent tool for the study of RIG-I agonists as vaccine adjuvants and a starting point in the development of such vaccine.
PMID:
23175362
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23175362